New results reveal MaaT013 (Xervyteg) achieved a one-year overall survival rate of 54% for the treatment of patients with refractory severe acute Graft-versus-Host Disease (aGvHD). The data was announced by biotechnology company MaaT Pharma at the American Society of Hematology (ASH) Annual Meeting and Exposition, currently taking place in Orlando, US. Read More
The European Medicines Agency (EMA) has granted orphan drug designation to ReAlta’s RLS-0071 (pegtarazimod) for the treatment of graft-versus-host disease (GvHD). The Orphan Drug Designation was supported by preliminary data from ReAlta’s ongoing Phase II trial, which included data from the initial cohort of steroid-refractory acute GvHD (aGvHD) patients. The… Read More
Adding a new drug to standard care for stem cell transplant recipients may reduce graft-versus-host disease (GvHD), according to an early-stage clinical trial conducted at Washington University School of Medicine in St Louis. The trial showed that patients being treated for various blood cancers tolerated the… Read More
The US Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD). It is approved for use after the failure of at least two prior lines of systemic therapy in adult and paediatric patients weighing at least… Read More
Researchers from Japan have identified a bacteriophage-derived enzyme that holds promise for future applications in preventing or treating acute graft-versus-host disease (aGVHD). Acute GVHD is a medical condition that occurs when donor immune cells attack the recipient’s tissues after an allogeneic hematopoietic stem cell transplantation (allo-HCT). Read More
The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Tr1X’s TRX103 for the prevention of Graft versus Host Disease (GvHD) in patients undergoing HLA-mismatched haematopoietic stem cell transplantation (HSCT). The company plans to initiate a Phase I study of the investigational allogeneic off-the-shelf… Read More
Mesoblast has resubmitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). Survival outcomes have not improved over the past two decades for the most severe forms of SR-… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we learned the shocking statistic that… Read More
News round-up for 7-11 November by DDW Digital Content Editor Diana Spencer This week we learned the shocking statistic that a third of scientific researchers have, or know a close colleague who has, experienced abuse after posting research online. It wasn’t all bad news, however, as top… Read More
BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial. The BioSenic autoimmune platform was created by Medsenic to target systemic autoimmune diseases using ATO as… Read More
